BTIG Research Reaffirms “Buy” Rating for Intuitive Surgical (NASDAQ:ISRG)

Intuitive Surgical (NASDAQ:ISRG)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a report issued on Wednesday, Benzinga reports. They presently have a $454.00 price target on the medical equipment provider’s stock. BTIG Research‘s target price would indicate a potential upside of 6.29% from the company’s current price.

Several other research firms have also issued reports on ISRG. Mizuho set a $415.00 price objective on shares of Intuitive Surgical in a research report on Tuesday, October 13th. Evercore set a $430.00 price target on shares of Intuitive Surgical in a research report on Monday, July 6th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 price target on shares of Intuitive Surgical in a report on Wednesday. Truist Financial reduced their price objective on Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Intuitive Surgical in a research note on Friday, August 21st. Twenty-five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $500.13.

Intuitive Surgical Stock Down 2.5%

Shares of ISRG stock traded down $10.89 on Wednesday, reaching $427.12. 3,129,969 shares of the stock were exchanged, compared to its average volume of 2,417,944. The stock has a market cap of $150.89 billion, a P/E ratio of 48.93, a price-to-earnings-growth ratio of 3.27 and a beta of 1.46. The firm has a 50 day moving average of $392.96 and a two-hundred day moving average of $409.06. Intuitive Surgical has a 1-year low of $328.57 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The firm’s revenue was up 21.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.40 earnings per share. On average, equities research analysts predict that Intuitive Surgical will post 8.87 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In related news, VP Fredrik Widman sold 1,089 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total value of $407,765.16. Following the transaction, the vice president owned 1,026 shares in the company, valued at approximately $384,175.44. The trade was a 51.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $375.57, for a total value of $28,918.89. Following the completion of the transaction, the executive vice president directly owned 881 shares of the company’s stock, valued at $330,877.17. This represents a 8.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 12,370 shares of company stock valued at $4,891,989. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Intuitive Surgical

A number of hedge funds have recently made changes to their positions in ISRG. Sowell Financial Services LLC grew its position in Intuitive Surgical by 6.0% during the 3rd quarter. Sowell Financial Services LLC now owns 4,497 shares of the medical equipment provider’s stock worth $1,829,000 after acquiring an additional 253 shares during the last quarter. Quadrant Capital Group LLC increased its position in Intuitive Surgical by 50.4% in the third quarter. Quadrant Capital Group LLC now owns 13,267 shares of the medical equipment provider’s stock worth $5,599,000 after purchasing an additional 4,448 shares during the period. Physician Wealth Advisors Inc. lifted its position in Intuitive Surgical by 136.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 154 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 89 shares during the period. Pinnacle Associates Ltd. raised its stake in shares of Intuitive Surgical by 37.4% during the third quarter. Pinnacle Associates Ltd. now owns 3,878 shares of the medical equipment provider’s stock worth $1,577,000 after buying an additional 1,056 shares during the last quarter. Finally, Harfst & Associates Inc. boosted its stake in Intuitive Surgical by 5.2% in the third quarter. Harfst & Associates Inc. now owns 4,290 shares of the medical equipment provider’s stock valued at $1,744,000 after acquiring an additional 212 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 revenue rose 21.7% year over year to $3.05 billion, while adjusted earnings of $3.00 per share exceeded analyst estimates. Worldwide procedures increased approximately 15%, and da Vinci system placements rose to 546 from 427 a year earlier, supporting the company’s underlying demand and growth trends. Intuitive Surgical Q3 earnings beat estimates
• Positive Sentiment: Several analysts remain bullish following the results. JPMorgan raised its price target to $475 and maintained an overweight rating; Baird increased its target to $550; and Bank of America reiterated a Buy rating with a $470 target. Analysts cited strong execution, extended-use instruments and Intuitive’s product pipeline. Bank of America reiterates Buy rating
• Neutral Sentiment: Intuitive plans to extend instrument life and reduce instrument pricing in 2027. The strategy could lower costs for hospitals and broaden robotic-surgery adoption over time, but management expects a 3%–5% reduction in revenue per procedure in the near term. Intuitive Surgical long-term investor takeaways
• Negative Sentiment: GAAP net income fell to $523 million, or $1.49 per share, from $704 million a year earlier because of the proposed antitrust settlement. The charge remains subject to court approval, adding uncertainty and weighing on reported profitability. Intuitive Surgical settlement coverage
• Negative Sentiment: Management narrowed its 2026 da Vinci procedure-growth forecast to 14%–15%, reflecting slower U.S. growth. The combination of moderating growth, lower future procedure economics and the legal charge explains why the stock decreased despite the earnings beat. Intuitive narrows 2026 procedure-growth outlook

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.